The eyes in diabetic patients displayed altered corneal biomechanics that may be related to blood glucose concentration. Further studies are required to establish the effects of long-term poor glucose control on corneal biomechanical properties and how this might affect the diabetic patient's response to refractive surgery procedures.

Purpose:To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits.Methods:The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL bevacizumab. Both eyes of four rabbits each time were enucleated at days 1, 3, 8, 15, and 29. Bevacizumab concentrations were measured in serum, aqueous humor, and vitreous.Results:Maximum vitreous (406.25 μg/mL) and aqueous humor (5.83 μg/mL) concentrations of bevacizumab in the right eye were measured at day 1. Serum bevacizumab concentration peaked at day 8 (0.413 μg/mL) and declined to 0.032 μg/mL at 4 weeks. Half-life values in right vitreous, right aqueous humor, and serum were 6.61, 6.51, and 5.87 days, respectively. Concentration of bevacizumab in the vitreous of the noninjected eye peaked at day 8 (0.335 ng/mL) and declined to 0.218 ng/mL at 4 weeks. In the aqueous humor of the noninjected eye, maximum concentration of bevacizumab was achieved at day 8 (1.6125 ng/mL) and declined (to 0.11 ng/mL) at 4 weeks.Conclusion:The vitreous half-life of 1.25 mg/0.05 mL intravitreal bevacizumab was 6.61 days in this rabbit model. Maximum concentrations of bevacizumab were reached at day 1 in both vitreous and aqueous humor of the right eye and at day 8 in the serum. Very low concentrations of bevacizumab were measured in the fellow noninjected eye.

The rate of RA loss (%/y) was greatest in the IT and ST sectors. However, because the nasal sectors contain more blood vessels (included in the HRT RA measurement), the percentage loss of neural tissue is underestimated in these sectors, to an unknown extent. The frequency of significant negative RA loss slopes was greatest in the ST, IN, and IT sectors. The finding suggests that all disc sectors should be evaluated for glaucomatous change in ocular hypertensive eyes.